Swiss ministers met with senior executives from Roche and Novartis to discuss the potential impact of U.S. import tariffs on pharmaceuticals. While pharmaceuticals currently avoid these tariffs, an ...

Swiss ministers have met with senior executives of pharmaceutical companies Roche and Novartis to discuss the outlook for the ...

The Swiss government met with executives of Roche Holding AG and Novartis AG to discuss the pharmaceutical industry’s situation in light of US tariffs.

Novartis Pharmaceuticals filed a lawsuit against the State of Rhode Island seeking to block the enforcement of a new state ...

Move follows Kirkland & Ellis withdrawal after conflict-of-interest challenge | Latham team led by new hire from Cravath.

Schuyler County is to receive a settlement from a New Jersey pharmaceutical company and its affiliates after the county argued it contributed to the ongoing opioid ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Novartis’ ianalumab has shown success in the third trial readout in two days, after it met both its endpoints in a Phase III ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its study goal, while Biogen and Stoke began a key Phase 3 test.

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

A multinational study shed light on which sites to scan for early signs of the disease, but scoring system was less sensitive ...

Novartis's Ianalumab Meets Goals in Phase 3 Trials to Treat Primary Immune Thrombocytopenia Novartis said its ianalumab drug combined with eltrombopag met the primary endpoint in a late-stage trial, ...